Ceftriaxone for Injection USP
American Pharmaceutical Partners Inc (Schaumburg, Ill) recently received 2 FDA approvals for its abbreviated new drug application for Ceftriaxone for Injection, with the FDA's clearance of the issues surrounding the raw material supplier for the product. The company also received approvals for 5 product codes for Ceftriaxone, the generic equivalent of Roche Pharmaceuticals' Rocephin. Ceftriaxone is a broad-spectrum antiinfective used to treat several types of bacterial infections including lower respiratory tract infections; acute bacterial otitis media; skin and skin structure infections; urinary tract infections; uncomplicated gonorrhea; pelvic inflammatory disease; bacterial septicemia; bone and joint infections; intra-abdominal infections; meningitis; and surgical prophylaxis. Ceftriaxone is preservative-free and AP-rated, and each vial will include a bar code and latex-free vial stopper. The product is available in 250-mg, 500-mg, 1-g, and 2-g single-dose vials, as well as a 10-g pharmacy bulk pack. For more information, visit www.appdrugs.com.
Exacta-Med Oral Dispenser
Baxa Corp (Englewood, Colo) recently launched the 35-mL Exacta-Med Oral Dispenser. The new dispenser size bridges the gap between the 20-and 60- mL dispensers, providing clinicians with greater flexibility for convenient preparation and safe administration of oral medications and enteral feedings. The 35-mL dispenser is well-suited for pediatric enteral applications. Numerous customer requests for a size between the 20-and 60-mL dispenser volumes prompted the development of the new 35-mL dispenser size. Exacta-Med Oral Dispensers play a vital role in preventing wrong-route administration of nonintravenous (non-IV) fluid drugs. The unique dispenser tips cannot connect to a Luer needle hub or a needleless IV system. Designed to ensure dose accuracy while preventing medication errors and wrongroute administration of IV drugs, oral dispensers and accessories are recommended by the Institute for Safe Medication Practice for use in oral and enteral fluid drug delivery. For more information, visit www.baxa.com, or call 800- 567-BAXA (800-567-2292).
EPS Inc (Ivyland, Pa) recently announced the addition of 9 new 6-mL screw cap bottles to its growing line of compounding and dispensing accessories. The bottles are ideal for respiratory therapy and nebulizer applications. The bottles are available in white, ultraviolet inhibitant, high-density polyethylene with an easy-to-screw cap. The cap is ribbed to allow for easy opening and closing. The product is available either blank or with 8 different imprints of commonly used respiratory therapy solutions. Custom imprints are also available. They are packaged in 100 bottles and caps per case. For more information, visit www.medidose. com, or call 800-523-8966.
Sensaphone (Aston, Pa) recently introduced its latest remote monitoring and alarm notification system?the Sensaphone 1800. The system is designed to protect pharmaceutical, laboratory, and vaccine management systems for the science and health lab industry. The product protects critical vaccines, blood storage, tissue samples, analytical and testing equipment, culture environments, and more by monitoring up to 8 environmental conditions. The Sensaphone 1800 offers enhanced features including the ability to sense and alarm on ultralow temperatures down to -85?C. When the product detects a problem, it automatically issues an alarm so action can be taken to avoid damage to a facility or its supplies of vaccines, medicines, and other critical materials. The new system delivers alarm notification to as many as 8 recipients and offers alarm history reviews, data logging, Webbased interface, and remote control capabilities. The product comes with custom voice messaging on any alarm event. The Sensaphone 1800 can also upload status and history to a Web server. For more information, visit www.sensaphone.com, or call 877-373-2700.
Correction: In the August 2006 issue of Pharmacy Times, the phone number for EPS Inc's ShrinkSafe ID Bands should have been 800-523-8966.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs